mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer

International Journal of Molecular Sciences

Volumn 16, Issue 2, 2015, Pages 3267-3282

  Wei, Feng ^a   Zhang, Yandong ^a   Geng, Li ^b   Zhang, Ping ^a   Wang, Guangyi ^a   Liu, Yan ^c  

^a JILIN UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Cell resistance; EGFR signaling; Feedback activation; FoxO1 3a; mTORC1 2 kinase; Pancreatic cancer

Indexed keywords

AZD 8055; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN KINASE B; PROTEIN S6; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; (5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; MORPHOLINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL LYSATE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME INHIBITION; FEEDBACK SYSTEM; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; MTT ASSAY; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MAMMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ERLOTINIB HYDROCHLORIDE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MORPHOLINES; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922289485     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16023267     Document Type: Article

References (42)

1. Vincent, A.; Herman, J.; Schulick, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607-620.
2. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA 2011, 61, 69-90.
3. Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605-1617.
4. Ryan, D.P.; Hong, T.S.; Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014, 371, 1039-1049.
5. Guertin, D.A.; Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12, 9-22.
6. Wei, F.; Liu, Y.; Guo, Y.; Xiang, A.; Wang, G.; Xue, X.; Lu, Z. Mir-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Mol. Cancer 2013, 12, 81.
7. Yao, J.C.; Phan, A.T.; Jehl, V.; Shah, G.; Meric-Bernstam, F. Everolimus in advanced pancreatic neuroendocrine tumors: The clinical experience. Cancer Res. 2013, 73, 1449-1453.
8. O'Reilly, K.E.; Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66, 1500-1508.
9. Sun, S.Y.; Rosenberg, L.M.; Wang, X.; Zhou, Z.; Yue, P.; Fu, H.; Khuri, F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65, 7052-7058.
10. Sun, S.Y. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 2013, 340, 1-8.
11. Thoreen, C.C.; Kang, S.A.; Chang, J.W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L.J.; Sim, T.; Sabatini, D.M.; Gray, N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284, 8023-8032.
12. Asahina, H.; Nokihara, H.; Yamamoto, N.; Yamada, Y.; Tamura, Y.; Honda, K.; Seki, Y.; Tanabe, Y.; Shimada, H.; Shi, X.; et al. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors: A dose-finding phase I study. Investig. New Drugs 2013, 31, 677-684.
13. Jordan, N.J.; Dutkowski, C.M.; Barrow, D.; Mottram, H.J.; Hutcheson, I.R.; Nicholson, R.I.; Guichard, S.M.; Gee, J.M. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res. 2014, 16, R12.
14. Preuss, E.; Hugle, M.; Reimann, R.; Schlecht, M.; Fulda, S. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. J. Biol. Chem. 2013, 288, 35287-35296.
15. Faber, A.C.; Coffee, E.M.; Costa, C.; Dastur, A.; Ebi, H.; Hata, A.N.; Yeo, A.T.; Edelman, E.J.; Song, Y.; Tam, A.T.; et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov. 2014, 4, 42-52.
16. Holt, S.V.; Logie, A.; Davies, B.R.; Alferez, D.; Runswick, S.; Fenton, S.; Chresta, C.M.; Gu, Y.; Zhang, J.; Wu, Y.L.; et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res. 2012, 72, 1804-1813.
17. Rodrik-Outmezguine, V.S.; Chandarlapaty, S.; Pagano, N.C.; Poulikakos, P.I.; Scaltriti, M.; Moskatel, E.; Baselga, J.; Guichard, S.; Rosen, N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of Akt signaling. Cancer Discov. 2011, 1, 248-259.
18. Keniry, M.; Parsons, R. mTOR inhibition, the second generation: ATP-competitive mTOR inhibitor initiates unexpected receptor tyrosine kinase-driven feedback loop. Cancer Discov. 2011, 1, 203-204.
19. Ke, L.D.; Adler-Storthz, K.; Clayman, G.L.; Yung, A.W.; Chen, Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 1998, 20, 320-327.
20. Fox, S.B.; Harris, A.L. The epidermal growth factor receptor in breast cancer. J. Mammary Gland Biol. Neoplasia 1997, 2, 131-141.
21. Mitsudomi, T.; Yatabe, Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010, 277, 301-308.
22. Raymond, E.; Faivre, S.; Armand, J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000, 60, 15-23.
23. Kim, T.E.; Murren, J.R. Erlotinib Osi/Roche/Genentech. Curr. Opin. Investig. Drugs 2002, 3, 1385-1395.
24. Chandarlapaty, S.; Sawai, A.; Scaltriti, M.; Rodrik-Outmezguine, V.; Grbovic-Huezo, O.; Serra, V.; Majumder, P.K.; Baselga, J.; Rosen, N. Akt inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19, 58-71.
25. Serra, V.; Scaltriti, M.; Prudkin, L.; Eichhorn, P.J.; Ibrahim, Y.H.; Chandarlapaty, S.; Markman, B.; Rodriguez, O.; Guzman, M.; Rodriguez, S.; et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-over-expressing breast cancer. Oncogene 2011, 30, 2547-2557.
26. Dansen, T.B.; Burgering, B.M. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008, 18, 421-429.
27. Myatt, S.S.; Lam, E.W. The emerging roles of forkhead box (FOX) proteins in cancer. Nat. Rev. Cancer 2007, 7, 847-859.
28. Buck, E.; Eyzaguirre, A.; Haley, J.D.; Gibson, N.W.; Cagnoni, P.; Iwata, K.K. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol. Cancer Ther. 2006, 5, 2051-2059.
29. Nyakern, M.; Cappellini, A.; Mantovani, I.; Martelli, A.M. Synergistic induction of apoptosis in human leukemia t cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol. Cancer Ther. 2006, 5, 1559-1570.
30. Liu, Y.; Sun, S.Y.; Owonikoko, T.K.; Sica, G.L.; Curran, W.J.; Khuri, F.R.; Deng, X. Rapamycin induces bad phosphorylation in association with its resistance to human lung cancer cells. Mol. Cancer Ther.2012, 11, 45-56.
31. Sirotnak, F.M.; Zakowski, M.F.; Miller, V.A.; Scher, H.I.; Kris, M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 2000, 6, 4885-4892.
32. Wang, X.; Hawk, N.; Yue, P.; Kauh, J.; Ramalingam, S.S.; Fu, H.; Khuri, F.R.; Sun, S.Y. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol. Ther. 2008, 7, 1952-1958.
33. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA 2013, 63, 11-30.
34. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA 2008, 58, 71-96.
35. Zhang, Y.J.; Dai, Q.; Sun, D.F.; Xiong, H.; Tian, X.Q.; Gao, F.H.; Xu, M.H.; Chen, G.Q.; Han, Z.G.; Fang, J.Y. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann. Surg. Oncol. 2009, 16, 2617-2628.
36. Garrett, J.T.; Chakrabarty, A.; Arteaga, C.L. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget 2011, 2, 1314-1321.
37. Sergina, N.V.; Rausch, M.; Wang, D.; Blair, J.; Hann, B.; Shokat, K.M.; Moasser, M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445, 437-441.
38. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 1999, 96, 857-868.
39. Kenyon, C.; Chang, J.; Gensch, E.; Rudner, A.; Tabtiang, R.A.C. Elegans mutant that lives twice as long as wild type. Nature 1993, 366, 461-464.
40. Kops, G.J.; de Ruiter, N.D.; de Vries-Smits, A.M.; Powell, D.R.; Bos, J.L.; Burgering, B.M. Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 1999, 398, 630-634.
41. Kurten, R.C.; Cadena, D.L.; Gill, G.N. Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science 1996, 272, 1008-1010.
42. Bae, G.Y.; Choi, S.J.; Lee, J.S.; Jo, J.; Lee, J.; Kim, J.; Cha, H.J. Loss of e-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget 2013, 4, 2512-2522.